ParkinsonCanadaV1, PascalFrancis, Curation, bibRecord, 000265

New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable

Identifieur interne : 000265 ( PascalFrancis/Curation ); précédent : 000264; suivant : 000266

New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable

Auteurs : A. Hadj Tahar [Canada] ; R. Grondin [Canada] ; L. Gregoire [Canada] ; F. Calon [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada]

Source :

Advances in neurology [ 0091-3952 ] ; 2003.

RBID : Pascal:03-0411829

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Dyskinésie, Traitement, Lévodopa, Chimiothérapie, Homme, Antiparkinsonien.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Chemotherapy, Dyskinesia, Human, Levodopa, Parkinson disease, Treatment.

A01	`01`	`1`		`@0 0091-3952`
A02	`01`			`@0 ADNRA3`
A03		`1`		`@0 Adv. neurol.`
A05				`@2 91`
A08	`01`	`1`	`ENG`	`@1 New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable`
A09	`01`	`1`	`ENG`	`@1 Parkinson's Disease`
A11	`01`	`1`		`@1 HADJ TAHAR (A.)`
A11	`02`	`1`		`@1 GRONDIN (R.)`
A11	`03`	`1`		`@1 GREGOIRE (L.)`
A11	`04`	`1`		`@1 CALON (F.)`
A11	`05`	`1`		`@1 DI PAOLO (T.)`
A11	`06`	`1`		`@1 BEDARD (P. J.)`
A12	`01`	`1`		`@1 GORDIN (Ariel) @9 ed.`
A12	`02`	`1`		`@1 KAAKKOLA (Seppo) @9 ed.`
A12	`03`	`1`		`@1 TERÄVÄINEN (Heikki) @9 ed.`
A14	`01`			`@1 Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ @2 Quebec @3 CAN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 6 aut.`
A14	`02`			`@1 The Institut Universitaire de Gériatrie de Montreal @2 Montreal, Quebec @3 CAN @Z 1 aut. @Z 4 aut.`
A14	`03`			`@1 Unité de Recherche en Oncologie and Endocrinologie Moléculaire, Centre de Recherche du CHUQ @2 Quebec @3 CAN @Z 4 aut. @Z 5 aut.`
A15	`01`			`@1 Research Centre, Orion Pharma, Orionintie 1 @2 02100 Espoo @3 FIN @Z 1 aut.`
A15	`02`			`@1 Department of Neurology, University of Helsinki @2 Helsinki @3 FIN @Z 2 aut. @Z 3 aut.`
A20				`@1 51-64`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 15741 @5 354000118596840050`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 127 ref.`
A47	`01`	`1`		`@0 03-0411829`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Advances in neurology`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B17G`
C02	`02`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Dyskinésie @5 04`
C03	`02`	`X`	`ENG`	`@0 Dyskinesia @5 04`
C03	`02`	`X`	`SPA`	`@0 Disquinesia @5 04`
C03	`03`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`03`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`03`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`04`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 18`
C03	`04`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 18`
C03	`04`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 18`
C03	`05`	`X`	`FRE`	`@0 Chimiothérapie @5 19`
C03	`05`	`X`	`ENG`	`@0 Chemotherapy @5 19`
C03	`05`	`X`	`SPA`	`@0 Quimioterapia @5 19`
C03	`06`	`X`	`FRE`	`@0 Homme @5 20`
C03	`06`	`X`	`ENG`	`@0 Human @5 20`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`07`	`X`	`FRE`	`@0 Antiparkinsonien @5 21`
C03	`07`	`X`	`ENG`	`@0 Antiparkinson agent @5 21`
C03	`07`	`X`	`SPA`	`@0 Antiparkinsoniano @5 21`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Système nerveux pathologie @5 41`
C07	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 41`
C07	`06`	`X`	`FRE`	`@0 Mouvement involontaire @5 42`
C07	`06`	`X`	`ENG`	`@0 Involuntary movement @5 42`
C07	`06`	`X`	`SPA`	`@0 Movimiento involuntario @5 42`
C07	`07`	`X`	`FRE`	`@0 Trouble neurologique @5 43`
C07	`07`	`X`	`ENG`	`@0 Neurological disorder @5 43`
C07	`07`	`X`	`SPA`	`@0 Trastorno neurológico @5 43`
N21				`@1 286`
N82				`@1 PSI`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A58

Links to Exploration step

Pascal:03-0411829

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable</title>
<author><name sortKey="Hadj Tahar, A" sort="Hadj Tahar, A" uniqKey="Hadj Tahar A" first="A." last="Hadj Tahar">A. Hadj Tahar</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>The Institut Universitaire de Gériatrie de Montreal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L." last="Gregoire">L. Gregoire</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F." last="Calon">F. Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>The Institut Universitaire de Gériatrie de Montreal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Unité de Recherche en Oncologie and Endocrinologie Moléculaire, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Unité de Recherche en Oncologie and Endocrinologie Moléculaire, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0411829</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0411829 INIST</idno>
<idno type="RBID">Pascal:03-0411829</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A58</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000265</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable</title>
<author><name sortKey="Hadj Tahar, A" sort="Hadj Tahar, A" uniqKey="Hadj Tahar A" first="A." last="Hadj Tahar">A. Hadj Tahar</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>The Institut Universitaire de Gériatrie de Montreal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L." last="Gregoire">L. Gregoire</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F." last="Calon">F. Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>The Institut Universitaire de Gériatrie de Montreal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Unité de Recherche en Oncologie and Endocrinologie Moléculaire, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Unité de Recherche en Oncologie and Endocrinologie Moléculaire, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Advances in neurology</title>
<title level="j" type="abbreviated">Adv. neurol.</title>
<idno type="ISSN">0091-3952</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Advances in neurology</title>
<title level="j" type="abbreviated">Adv. neurol.</title>
<idno type="ISSN">0091-3952</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Dyskinesia</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Traitement</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Homme</term>
<term>Antiparkinsonien</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0091-3952</s0>
</fA01>
<fA02 i1="01"><s0>ADNRA3</s0>
</fA02>
<fA03 i2="1"><s0>Adv. neurol.</s0>
</fA03>
<fA05><s2>91</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG"><s1>New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Parkinson's Disease</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>HADJ TAHAR (A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GRONDIN (R.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GREGOIRE (L.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CALON (F.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DI PAOLO (T.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BEDARD (P. J.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>GORDIN (Ariel)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>KAAKKOLA (Seppo)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="03" i2="1"><s1>TERÄVÄINEN (Heikki)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>The Institut Universitaire de Gériatrie de Montreal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Unité de Recherche en Oncologie and Endocrinologie Moléculaire, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Research Centre, Orion Pharma, Orionintie 1</s1>
<s2>02100 Espoo</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Department of Neurology, University of Helsinki</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA15>
<fA20><s1>51-64</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>15741</s2>
<s5>354000118596840050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>127 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0411829</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Advances in neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>19</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>19</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>19</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>21</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>21</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>21</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>43</s5>
</fC07>
<fN21><s1>286</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000265 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000265 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:03-0411829
   |texte=   New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable

New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri